SUMMARY Blood concentration and urinary excretion of captopril following SO mg oral administration were determined by high-performance liquid chromatography In normal subjects and patients with chronic renal failure. In normal subjects, the iwrimum blood concentration of the free form of captopril was obtained -within 1 hour and was not detectable after 6 hours; 41% of administered captopril was excreted into the urine as free form and metabolites within 2 hours, and 58% within 6 hours. In chronic renal failure patients with an average serum creatinine of 5.1 mg/dl, the absorption constant (Ka), maximum concentration (Cmax), and area under the blood concentration curre (AUC) were not significantly different from those in the normal subjects, but the elimination constant (Ke) and biological half-life (T 1/t ) showed a significant delay in the disappearance of captopril from the blood (p < 0.01 respectively). The cumulatire amount of urinary excretion of either free-form captopril or its' metabolites was significantly decreased at 2,4, and 6 hours in chronic renal failure patients (p < 0.01 or less, respectively). Impairment of kidney function is suggested to be an important factor In the promotion of blood retention of captopril. 
C APTOPRIL (SQ 14,225), a converting enzyme inhibitor, has a potent antihypertensive effect in patients with renovascular and essential hypertension and hypertension with chronic renal failure (CRF) through its vasodilator action without deterioration of kidney function. 1 " 8 In hypertensive emergency the combination therapy of captopril and diuretics is particularly useful. 1 Recently the side effects of captopril such as fever and rash were reported to be important complications, which sometimes necessitate discontinuation of the drug. 1 -*• 4> • The pharmaceutical company (Sankyo, Japan) from which we obtained the drug recommends not using it in cases with a serum creatininc level higher than 8 mg/dl. Hypertensive emergency is said to be the best indication for the drug, but occasionally impairment of renal function also occurs. It is important to investigate pharmacokinetic characteristics and urinary excretion in subjects with different renal function in order to investigate the precise indication for use of this drug.
Subjects and Methods
We studied five volunteers with normal renal function and seven CRF patients with an average serum creatinine of 5.1 ± 1.1 mg/dl (table 1) . Renal biopsy showed the original cause of the renal failure to be chronic glomerulonephritis. After 1 hour of supine rest in the early morning while fasting, 50 mg of captopril was administered periorally with 100 ml of water; 3 ml of venous blood was taken before, and 30, 60, 120, 180, 240, and 360 minutes after this captopril administration. In normal volunteers, blood samples were drawn at 20 and 40 minutes instead of at 30 minutes after drug administration. Urine was collected every 2 hours before and at 2,4,6 hours after the administration. The concentration of captopril in the blood and urine was measured according to the newly developed method by Kawahara et 8.6 ± 1.5 Results expressed as mean ± SEM. S-Creati = serum creatinine; N = normal; CRF = chronic renal failure; GOT = glutamic oxaloacetic transaminase; GPT = glutamic pyruvic transaminase. *p < 0.02 vs N.
Assay Procedure: Free Form of Captopril in Whole Blood One ml of freshly drawn blood was immediately mixed with 0.5 ml of p-bromophenacyl bromide (2.5 mg/ml in acetone). The tube contents were kept for 5 minutes at room temperature to make complete adduct formation of captopril. Glutathione (5 mg/ml in water, 0.25 ml) was added to the mixture to remove the excess of reagent. After washing with hexane, the mixture was acidified and extracted twice with 6 ml of benzene. The organic layer was evaporated to dryness. The final residue was dissolved in acetonitrile and assayed by HPLC equipped with ^-Bondapak C u column using mobile phase consisting of acetonitrileacetic acid-water mixture (48-51.5-0.5).
Assay Procedure: Free Form and Metabolites of Captopril in Urine
Five ml of urine was mixed with 0.5 ml of p-bromophenacyl bromide (20 mg/ml in methanol) to produce a stable adduct of captopril. Disulfides such as SQ 14,551 and mixed disulfides in urine were converted to SQ 14,225 by treating with tributyl phosphine (100 mg/ml in methanol, 0.1 ml) at 50°C for 30 minutes. The converted SQ 14,225 was trapped with 0.2 ml of N-(4-dimethylamino-3,5-dinitrophenyl) maleinide (2 mg/ml in acetone). Those two kinds of adduct of SQ 14,225 were extracted twice with 6 ml of benzene. The organic layers were evaporated to dryness. The HPLC was used for the determinations. Accumulations of free form and metabolite were expressed as total form in the results.
The results are shown as mean ± SEM; statistical significances of differences between the groups were assessed by Student's t test.
Results
The blood concentration of captopril is illustrated in figure 1 . At 1 hour after administration the maximum blood concentration was 364 ± 64 ng/ml in the normal group and 342 ± 76 ng/ml in the CRF group. No significant difference was noted between the groups. At 2 hours and at 4 hours, the blood concentration of captopril was significantly higher in the CRF group than the normal group (p < 0.05, respectively). At 6 hours, captopril was undetectable in all subjects of the normal but it was measurable in four patients of the CRF group.
Pharmacokinetic analysis was performed as one compartment open model using Nonlinear least square methods.
1 Absorption constant (Ka) was 2.32 ± 0.34 per hour in the normal group and 7.18 ± 2.87 in the CRF group. The elimination constant (Ke) was 2.03 ±0.13 per hour in the normal group and 1.02 ± 0.11 in the CRF group, and the latter was significantly smaller than the former (p < 0.001). The biological half-life (T 1/9 ) of 0.74 ± 0.09 hours in the CRF group was significantly longer than that in the normal group (0.35 ± 0.02, p < 0.01). The maximum concentration (Cmax) was not different between the two groups: 389 ± 87 ng/ml in the normal group and 432 ± 59 ng/ml in the CRF group. The time at which the maximum concentration was reached (Tmax) was 0.74 ± 0.05 hours in the normal group and 0.93 ±0.19 hours in the CRF group. The area under the blood concentration curve [AUC]go was larger in the CRF group (793 ±131 ng'hr/ml) than in the normal group (479 ± 85 ng»hr/ml), but the difference was not statistically significant.
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FIGURE 1. Blood concentration of free form of captopril (B Cone) at serial time intervals after 50 mg oral administration in patients with chronic renal failure (CRF) and in normal subjects (N). Circle and bar show mean ± SEM
FIGURE 2. Cumulative urinary excretion of captopril (U Excr), free form (Free) and total form (Total) at serial time intervals after 50 mg oral administration in patients with chronic renal failure (CRF) and in normal subjects (N). Circle and bar show mean ± SEM * = p < 0.01 or less vs N.
Cumulative amounts of free form and total form of captopril in the urine are illustrated in figure 2. In the normal group, the excretion of captopril through the kidney, as either free or total form, was high during the first 2 hours and lower thereafter. Excretions in the CRF group were significantly decreased in both fractions at every time interval when compared with those in the normal group (p < 0.01 or less). In the CRF group, the total excretion of the free form of captopril during the 6 hours of study was 20.4% of that in the normal group, and the total excretion of total form of captopril was 27.7% of that in the normal group.
Discussion
There have been no reports about the blood concentration and urinary excretion of captopril in patients with renal functional impairment. In this study, a significantly prolonged retention of captopril in the circulating blood was observed in the CRF group, without a difference in the maximum level of blood concentration. Recently Kripalani et al. e reported the pharmacokinctics of captopril in normal subjects using 100 mg of "S-labeled captopril, where Cmax was 800 ng/ml, Tmax was 0.93 hours, and AUC was 1150 ng hr/ml. Since their study used twice the amount of captopril, Cmax and AUC revealed dosedependent higher values than those in this study in normal subjects. Also, it can be said that the pharmacokinetic values of our study in the CRF group given 50 mg of captopril seem to equal those of their study in normal subjects given 100 mg.
The method we developed can detect unchanged, free form of captopril in the blood. The blood compositions of unchanged captopril and disulfides dimer were reported to be 52% and 10% of the total radioactivity at 1 hour after administration; the remainder was present as polar metabolites.' As the disulfides and metabolites can be suggested to have a hypotensive effect, as well, the data obtained in this study may not be enough to explain the total depressor effect of captopril.
Apparent disturbances were not observed in the route for ingestion of the drug in the whole of this study group. Liver function was also normal. Excretion through feces in normal subjects after 24 hours* was reported to be 2.96% of the dose administered. Significant delay of elimination and prolongation of biological half-life, which were derived from the size of the elimination constant, were considered to be caused by the significant decrease of urinary excretion of the drug. Our study suggests that the renal excretory function is an important factor in the promotion of the retention of captopril in the body.
Four cases of toxic reactions to this drug were documented in previous reports. The manifestations described in these papers were fever and generalized morbiliform rash, 1 rash,* fever and macular rash, 4 and erythematous macular rash. 5 The appearance of these manifestations was said to be dose-dependent, as it could be diminished by decreasing the amount of the drug administered. 1 ' *• *•' However, in two cases,* 1 * serum creatinine was found to be high; we also found that six of nine patients with accelerated or malignant hypertension and an elevated serum creatinine of 5.9 mg/dl or more had macular or follicular rashes associated with high fever. Since in this study the single administration of a small dose of captopril showed significantly high blood retention in the subjects with CRF, it is possible that in such cases with renal impairment the administration with a dosage of clinical use will cause retention and result in the complication, although the true mechanism can not be clarified.
Captopril has a potent vasodilator action* and is the best indication for malignant or accelerated hypertension. The combination with sodium deprivation by diuretics, especially furosemide, is suggested in such cases to obtain good control of blood pressure with the minimal requirement of captopril. l> * As was found by Brunncr et al.,' a dose increase of captopril from 25 to 200 mg did not enchance the amplitude of the antihypertensive effect but did increase its duration in hypertensive patients. We can expect further prolongation of the effectiveness of captopril in patients with end-stage renal failure. The decrease of frequency of daily administration should prevent serious complications in cases with renal impairment.
